Delivery Order SPE2DP18D0011-SPE2DP18F6019
Award Date
9/24/18
Potential Completion Date
9/24/19
Potential Value
$77K
Federal Agency
Medical Supply Chain
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, SPE2DP16D0008|0051, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The $76,496.94 firm-fixed-price delivery order is for the supply of oseltamivir phosphate, an antiviral medication, with a period of performance through September 11, 2018. Genentech holds several major contract vehicles with federal agencies like the Department of Veterans Affairs and the Department...
This federal contract award, SPE2DP18D0011|SPE2DP18F6016, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The contract, valued at $115,959.93, is for the delivery of oseltamivir phosphate, a critical antiviral medication. The contract is a firm fixed-price Delivery Order, with a completion date of August 3, 2023. Genentech USA, Inc. has previously received several significant federal contract...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $85,938.87. The contract has a firm fixed price and does not utilize any set-aside designations. Genentech has several existing contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule...
This federal contract award, SPE2DP16D0008|0021, was made by the Medical Supply Chain division of the Defense agency to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $101,188.26 firm-fixed-price delivery order is for the antiviral medication oseltamivir phosphate, with a performance period ending on September 22, 2017. The award is not associated with a set-aside program. Genentech USA, Inc. is a major supplier of pharmaceuticals and biologics to federal...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a biotechnology company and manufacturer of pharmaceuticals based in South San Francisco, California. The contract is for the supply of oseltamivir phosphate, an antiviral medication, with a ceiling value of $87,034.98. The contract is a firm-fixed-price delivery order that was awarded on September 28, 2016, with a completion date of September 28, 2017. The contract was not set aside for any...
This is a $112,687.80 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract is not designated as a set-aside. Genentech holds several key contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule with the Department of Veterans Affairs for pharmaceutical products, and a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract has a firm fixed price, with a ceiling value of $88,842.60, and was awarded on September 8, 2017 with a completion date of September 10, 2018. The contract was not set aside for any special designation. Genentech holds several key contract vehicles with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the supply of oseltamivir phosphate, an antiviral medication, with a total ceiling value of $259,393.47. The contract is a firm-fixed price delivery order with a completion date of September 20, 2017. Genentech is the prime contractor, and no major subcontractors were identified. The contract is...
This is a $92,304 firm-fixed-price delivery order awarded by the Department of Defense's Medical Supply Chain to Genentech USA, Inc. for the pharmaceutical product oseltamivir phosphate. The contract has no set-aside designation. Genentech is a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics that provides a wide range of products to federal agencies through various contract vehicles, including a $4.9 billion Federal Supply Schedule with the Department of Veterans...
This federal contract award, SPE2DP18D0011|SPE2DP18F6081, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The $93,573.18 firm-fixed-price delivery order is for the supply of the antiviral medication oseltamivir phosphate, also known as Tamiflu. This award does not have a set-aside designation. Genentech is an established contractor providing pharmaceuticals and biologics to federal agencies through various contract...